David Meeker appointed as chief executive of Genzyme
pharmafile | October 25, 2011 | Appointment | Research and Development, Sales and Marketing | Genzyme, Sanofi
Sanofi has appointed David Meeker as chief executive of its new biotech acquisition Genzyme.
He will report to Christopher Viehbacher, Sanofi’s chief executive, and will join the group management committee whilst Viehbacher will retain the position of chairman of Genzyme.
He will replace Henri Termeer, previously chief executive and chairman of Genzyme who left the firm after its merger with Sanofi earlier this year.
Under Meeker’s leadership, Genzyme will incorporate the rare disease business and the multiple sclerosis franchise.
Previous Genzyme divisions – renal, biosurgery and oncology – have been integrated within the existing Sanofi portfolio giving them greater global scale.
David joined Genzyme in 1994 as medical director to work on the cystic fibrosis gene therapy programme.
In 2009, he was promoted to chief operating officer of Genzyme and has played an important role in the integration since April of this year.
Viehbacher said: “After working closely with David over the past six months, I am confident that he is the best person to lead Genzyme.
“David’s commitment to employees, physicians and patients has been a key success factor in the successful integration of Genzyme as part of the Sanofi Group.
“His combination of medical and business experience will be essential to move Genzyme’s broad portfolio of products forward and deliver much-needed therapies to patients.”
Related Content

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …

Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …

Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …






